The In Vivo Cell Engineering & Gene Editing Summit explores advancements in in vivo cell engineering and gene editing, focusing on innovative therapies, delivery technologies, and clinical translation.
Key Topics
Exploring the possibilities of in vivo gene editing to diversify treatment opportunities
Leveraging delivery model insights to engineer enhanced delivery vehicles to refine target specificity & reduce immunogenicity
Reimagining CAR & protein manufacturing processes to revolutionize treatment payload manufacturing
Industry leader’s fireside chat: navigating the path to the clinic to accelerate clinical efficacy
Investigating strategies to refine translational outcomes & direct future advancements
Envisioning the future evolution of in vivo hematopoietic stem cell engineering & gene editing treatments
Unlocking novel strategies & technologies to produce targeted, stable vehicle delivery options & stimulate clinical progression
‘Evaluating LVV & LNP delivery method clinical potential in in vivo cell & gene therapies
Shaping the next generation of in vivo gene editing
Exploring treatment engineering approaches to overcome off-target toxicity
Translating & harnessing key learnings from ex vivo therapies to supercharge in vivo clinical progression
Keynote presentation: unveiling transformative IND data to supercharge the clinical progression of in vivo cell engineering & gene editing therapies
Navigating protein delivery mechanisms to overcome tolerance & immunogenicity
Reimagining gene editing capabilities: exploring in situ gene editing of the microbiome to expand addressable targets
Keynote presentation: highlighting Myeloid’s groundbreaking clinical experience with the first in vivo CARs applied to humans
